期刊
EUROPEAN FOOD RESEARCH AND TECHNOLOGY
卷 229, 期 4, 页码 561-569出版社
SPRINGER
DOI: 10.1007/s00217-009-1083-3
关键词
Angiotensin I-converting enzyme inhibitory peptide; Blood pressure; Nutraceutical; Functional food
资金
- Ocean Nutrition Canada (Private Company)
- National Research Council of Canada-Industrial Research Assistance Program (NRC-IRAP)
A salmon protein hydrolysate (SPH) was developed containing several angiotensin I-converting enzyme (ACE) inhibitory tripeptides the most abundant of which were Val-Leu-Trp, Val-Phe-Tyr, and Leu-Ala-Phe. Simulated digestion experiments showed that active constituents of SPH would survive in the digestive tract and be available for absorption into the bloodstream. In fact, ACE inhibitory activity was improved following simulated digestion suggesting that there were larger peptides in SPH that might contribute to bioactivity in vivo. A single oral dose (1,500 mg/kg body mass) of SPH significantly lowered blood pressure in spontaneously hypertensive rats (SHR). The treatment of SHR with either SPH fraction (< 3,000 Da) or SPH fraction (> 3,000 Da) reduced blood pressure. We conclude that the ability of SPH to lower blood pressure is due to a combination of ACE inhibitory tripeptides as identified, as well as additional unknown, peptide species that are generated during digestion of SPH in the gastrointestinal tract.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据